Karyopharm Reports Updated Phase 2b SADAL Data for Selinexor in Diffuse Large B-Cell Lymphoma at the 2017 European Hematology Association Annual Meeting
(WorldNews Health)

Objective Response Rate Increases to 33.3% Overall and is 35% in Patients with `Double- or Triple-Hit` DLBCL With Additional Responders, Median Duration of Response Remains Greater than 7 Months Top-Line Data from SADAL Study Expected in the Second Half of 2018 NEWTON, Mass., June 23, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported updated clinical data from the ongoing Phase 2b Selinexor Against Diffuse Aggressive Lymphoma (SADAL) study evaluating lead product candidate, selinexor (KPT-330), an oral Selective Inhibitor of Nuclear Export / SINETM compound, in patients with relapsed or refractory diffuse large B-cell...